NCT07047664Not yet recruiting
KERMIT: Sweat Patch for Early Kidney Disease Detection
Kidney Disease Sweat Sensor Patch for Early Diagnosis and Remote MonIToring
Source: ClinicalTrials.gov · Last updated 2 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Chronic kidney disease (CKD) affects over 10% of the global population, leading to significant morbidity, mortality, and economic burden. Early detection is crucial for preventing disease progression and complications; however, awareness and diagnosis of CKD remain alarmingly low. Current methods rely on blood or urine analysis, which are invasive and require specialized facilities. The KERMIT patch aims to address this gap by providing a wearable lab-on-a-chip device capable of measuring key biomarkers from sweat non-invasively. This innovation has the potential to revolutionize CKD diagnosis, particularly in remote or underserved areas. The KERMIT patch integrates functional printed biosensors, a high-frequency electrochemical microchip, and a sustainable microfluidic system. Sensors are fabricated using carbon inks and 2D materials, enabling immunodetection and non-enzymatic sensing of creatinine, urea, and cystatin C. Preliminary tests evaluated detection limits, skin compatibility, and carbon footprint.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 3 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- University of Ioannina
- Diseases
- Chronic kidney disease
- NCT number
- NCT07047664
What you commit to
- Study type: Interventional
- Planned participants: 52
- From 1 Jul 2025 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving immunosuppression treatment;
- Patients with metal implants;
Other illness
- Any signs of dermal infections, open wounds, or skin irritation.
- Patients with uncontrolled hypertension (a systolic blood pressure (SBP) \>150 mmHg and/or diastolic blood pressure (DBP) \>90 mmHg with measurements taken under standardized conditions (e.g after a 5-minute seated rest, using validated equipment);
- Known allergy to pilocarpine,
- Active malignancy;
Lab values
- Significant variations in eGFR in the last two months, defined as any absolute change (either increase or decline) in eGFR of \>10 mL/min/1.73m2 ;
- Patients receiving drugs reported to affect serum levels of creatinine and cystatin-c without affecting kidney function (i.e. cimetidine, trimethoprim, and fibrates);
Other
- Patients with a functioning kidney graft;
- Patients with kidney stones;
- Glaucoma;
- Pregnancy;
- Low life expectancy (\<6 months) according to investigators judgement
Who the study is looking for
- Adults aged ≥18 years with stable CKD, defined as:
- eGFR \< 60 mL/min/1.73 m², or
- eGFR ≥ 60 mL/min/1.73 m² with documented evidence of kidney damage (persistent albuminuria, structural abnormalities on imaging or histology, or genetic kidney disease).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.